Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

2 days ago

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

3 weeks ago

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

4 weeks ago

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

5 weeks ago

Ze­ta­gen Fights Breast Can­cer Where it Lives…

Last month

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py in Chi­na

Last month

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Last month

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

Last month

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

2 months ago

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

2 months ago

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

2 months ago

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse pop­u­la­tions

2 months ago

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

3 months ago

Obe­si­ty drug de­vel­op­ment—still room to grow

4 months ago

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

4 months ago

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

4 months ago

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

4 months ago

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

4 months ago

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

5 months ago

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

5 months ago

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

7 months ago

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

7 months ago

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

8 months ago

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

8 months ago
1234 Next page Last page
A service from the Financial Times